Starpharma (SPL) reported that AstraZeneca has commenced a phase 1 clinical trial of AZD0466 (DEP Bcl2/xL conjugate) and the first patient has been successfully dosed. The development of AZD0466, is being progressed under a multi-product license whereby Starpharma is eligible to receive development, launch and sales milestones of up to US$124 million, plus tiered royalties on net sales. The first dose of AZD0466 administered in the phase 1 trial has triggered a milestone payment to Starpharma of US$3 million
http://crweworld.com/article/news-provided-by-business-wire/1363908/starpharma-commencement-of-phase-1-trial-for-azd0466-utilising-dep-delivery-technology
- Forums
- ASX - By Stock
- Ann: Commencement of phase 1 trial for AZD0466 utilising DEP
Starpharma (SPL) reported that AstraZeneca has commenced a phase...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.0¢ |
Change
-0.005(4.00%) |
Mkt cap ! $49.44M |
Open | High | Low | Value | Volume |
12.0¢ | 12.5¢ | 12.0¢ | $34.86K | 289.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 263226 | 12.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.5¢ | 57773 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 253226 | 0.120 |
8 | 628274 | 0.115 |
6 | 197444 | 0.110 |
9 | 301213 | 0.105 |
10 | 301472 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.125 | 57773 | 3 |
0.130 | 272057 | 8 |
0.135 | 65776 | 5 |
0.140 | 128397 | 8 |
0.145 | 200605 | 6 |
Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
Last
12.5¢ |
  |
Change
-0.005 ( 4.17 %) |
|||
Open | High | Low | Volume | ||
12.0¢ | 12.5¢ | 12.0¢ | 6229 | ||
Last updated 15.59pm 07/05/2024 ? |
Featured News
SPL (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online